On Friday, Viridian Therapeutics Inc (VRDN) stock saw a decline, ending the day at $20.14 which represents a decrease of $-1.50 or -6.93% from the prior close of $21.64. The stock opened at $21.72 and ...

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) today and set a price ...

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Viridian Therapeutics (VRDN – Research Report) on November 12 and set a ...

Third Quarter 2024 Results Key Financial Results Net loss: US$76.7m (loss ...

Viridian Therapeutics ( (VRDN)) has issued an update. Viridian Therapeutics, a biotech company, highlights its recent advancements in treating thyroid eye disease (TED) and FcRn inhibitor ...

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.09 per share a year ago. These ...

Viridian Therapeutics, Inc.'s VRDN-001, now Veligrotug, shows promising phase 3 data in Thyroid Eye Disease, outperforming Tepezza in early stages and targeting both active and chronic TED.

November 12, 2024--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

At the other end of the spectrum, the biggest loser in the cannabis investment wheel was hemp, which drew just two capital raises in the past year, down from 11 the year prior, an 82% decline. The ...

During the last three months, 11 analysts shared their evaluations of Viridian Therapeutics (NASDAQ:VRDN), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering ...